HEGGIE THERESA 4

What Happened Theresa Heggie, a non-employee director of BioCryst Pharmaceuticals, received automatic director compensation on 2026-06-11: 15,294 restricted stock units (RSUs) and 33,540 stock options. Both items were reported as awards (transaction code A) with an acquisition price of $0.00 (non-cash grants). These were grants, not purchases or sales.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-15 (filed within the two-business-day reporting window).
• Grants: 15,294 RSUs (reported at $0.00) and 33,540 derivative securities (stock options) (reported at $0.00).
• Vesting: RSUs will vest on the first anniversary of the grant per footnote F1. Footnote F2 confirms the options were automatic non-employee director option grants under the Director Compensation Policy.
• Shares owned after transaction: not specified in the provided filing details.
• Transaction codes: A = Award/Grant. This was a grant, not an exercise or sale.

Context These awards are routine non-employee director compensation under BioCryst’s Director Compensation Policy and do not represent an open-market purchase or sale. The option grant is a derivative award (a right to buy shares in the future); it was granted, not exercised, so no shares were sold or purchased in cash at this time. Such routine director grants are common and should be viewed as compensation rather than a direct signal of trading intent.